Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: a systematic review and meta-analysis

Advances in immunological treatment challenged the management of cancer patients in the last decade [1]. Immune checkpoint molecules, including the programmed cell death protein (PD-1) and cytotoxic T-Lymphocyte Antigen 4 (CTLA4), control immune responses within the tumor microenvironment. Targeting the PD-1 and CTLA4 receptors on T cells has demonstrated therapeutic efficacy in different cancer types, but only subgroups of patients have durable responses. Hence, understanding their benefit/risk is of paramount importance in a routine activity to set their therapeutic role [1 –5].

Source: Cancer Treatment Reviews - August 18, 2021 Category: Cancer & Oncology Authors: Michela Giustozzi, Cecilia Becattini, Fausto Roila, Giancarlo Agnelli, Mario Mandal à Source Type: research